The Patient in Your Alzheimer’s Disease Study May be in Another: Duplication and Deception in Clinical Trials of Alzheimer’s Disease
Duplicate and deceptive subjects, a significant issue in CNS studies, are not often considered in Alzheimer’s Disease (AD) clinical trials. However, AD patients and their study partners may be motivated to take advantage of different mechanisms of action, increase odds of receiving active treatment, and/or obtain financial compensation, which may lead them to participate in multiple studies. CTSdatabase reviewed memory loss subjects (n=1087) from January 2017 through May 2019 to determine how many attempted to screen at multiple sites. 117 subjects (10.8%) visited more than one site within two years. When these potential AD subjects went to additional sites, it was predominantly for non-memory indications (often MDD or schizophrenia). For those that participated in studies, the rate of duplication approached 4% of screened AD subjects. This data indicates that significant numbers of AD subjects attempt to enroll at multiple sites, which confounds efficacy and safety signals in clinical trials.
Key wordsProfessional research subject deception duplicate subjects dual enrollment
Funding: There is no outside funding for this report. Ms. Steinmiller, Ms. Steinmetz and Ms. Perez are employees of CTSdatabase, LLC.
Conflict of interest disclosure: Dr. Shiovitz has ownership interest in and is President of CTSdatabase, LLC.
Ethical standards: All data reported in this study has been collected from patients who have signed an appropriate IRB or Ethics Committee approved consent form.
- 6.Shiovitz TM, Fox BL, Steinmetz CB, et al. Now I Remember! (That I’m in Another Study): Duplicate Subjects in Clinical Trials of Alzheimer’s Disease, Clinical Trials on Alzheimer’s Disease Annual Meeting. November 2, 2017, Boston, MA. Poster.Google Scholar
- 7.Home — ClinicalTrials.gov. http://clinicaltrials.gov/. Accessed 2019-09-23.
- 9.Chertkow H. An Action Plan to Face the Challenge of Dementia: International Statement on Dementia from IAP for Health. J Prev Alzheimer’s Dis. 2018;5(3):207–212.Google Scholar
- 10.Lee Y. Primary Prevention of Dementia: The Future of Population-Based Multidomain Lifestyle Interventions. J Prev Alz Dis 2018;5(1):5–7Google Scholar
- 11.Aisen PS. Failure After Failure. What Next in AD Drug Development? J Prev Alz Dis 2019;6(3):150.Google Scholar
- 12.Anstey KJ, Peters R. Oversimplification of Dementia Risk Reducation Messaging is a Threat to Knowledge Translation in Dementia Prevention Research. J Prev Alz Dis 2018;5(1):2–4.Google Scholar
- 17.Hanson E. Hudgins B, Tyler D, et al. A method to identify suvjects who attempt to enroll in more than 1 trial within a drug development program and preliminary review of subject characteristics. Poster presented at CNS Summit; November 2011; Boca Raton, FL.Google Scholar
- 18.Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. Draft Guidance issued June,2019.Google Scholar